Internal Medicine, Rheumatology · Garden Grove, CA
NPI
1932162385
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
13872 Harbor Blvd, Unit 1a
Garden Grove, CA, 92843
Phone (714) 210-1300
Groups this clinician bills Medicare through
Medicare paid, 2024
$255K
4,080 services
Medicare patients, 2024
833
Average age 75
Drug cost, 2024
$10.4M
10,089 prescriptions
Company payments, 2025
$5,855
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David D Dang was code 99214 (office e&m - established), 1,706 times for 729 patients. In total David D Dang billed 4,080 services in 12 codes, and Medicare paid $255K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,706 | 729 | $108.20 | $185K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,514 | 284 | $0.77 | $1,173 |
| 20610 Joint Injection | Office | 296 | 194 | $55.37 | $16K |
| 99205 Office E&M - New | Office | 128 | 128 | $185.23 | $24K |
| 99213 Office E&M - Established | Office | 116 | 93 | $78.38 | $9,092 |
| 20605 Joint Injection | Office | 84 | 69 | $47.42 | $3,983 |
| 20600 Joint Injection | Office | 69 | 49 | $45.21 | $3,119 |
| 99204 Office E&M - New | Office | 62 | 62 | $135.86 | $8,423 |
| 99211 Office E&M - Established | Office | 59 | 23 | $20.86 | $1,231 |
| 93000 Electrocardiogram | Office | 24 | 24 | $12.42 | $298 |
| 99215 Office E&M - Established | Office | 21 | 21 | $146.67 | $3,080 |
By year: 2022 $284K for 4,727 services; 2023 $269K for 4,451 services; 2024 $255K for 4,080 services.
Medicare prescription drug claims, 2024
In 2024, the drug David D Dang prescribed most often to Medicare patients was Gabapentin, with 1,101 prescriptions and refills. In total David D Dang wrote 10,089 Medicare prescriptions that cost $10.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 1,101 | 1,525 | 275 | $6,469 |
| Celecoxib Generic | 920 | 1,162 | 214 | $19K |
| Famotidine Generic | 818 | 1,846 | 273 | $6,246 |
| Tramadol Hcl Generic | 641 | 666 | 161 | $1,346 |
| Methotrexate Methotrexate Sodium | 505 | 637 | 69 | $5,703 |
| Diclofenac Sodium Generic | 409 | 443 | 94 | $51K |
| Rinvoq Upadacitinib | 404 | 414 | 43 | $2.5M |
| Hydroxychloroquine Sulfate Generic | 402 | 808 | 94 | $15K |
| Enbrel Sureclick Etanercept | 372 | 372 | 39 | $2.7M |
| Allopurinol Generic | 307 | 664 | 88 | $1,380 |
| Tizanidine Hcl Generic | 277 | 337 | 71 | $1,457 |
| Alendronate Sodium Generic | 272 | 395 | 58 | $996 |
| Prolia Denosumab | 244 | 1,464 | 136 | $397K |
| Ibuprofen Generic | 212 | 242 | 73 | $1,183 |
| Prednisone Generic | 200 | 263 | 67 | $780 |
Brand drugs: - claims; generic drugs: 7,904 claims; opioid claims: 767.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David D Dang $5,855 ($5,855 in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $1,743.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 63 | $1,743 |
| Amgen Inc. AMGN | 36 | $946 |
| Genzyme Corporation SNY | 14 | $679 |
| Janssen Biotech, Inc. JNJ | 19 | $615 |
| Aimmune Therapeutics, Inc. | 26 | $423 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $343 |
| Lilly USA, LLC LLY | 13 | $319 |
| Pfizer Inc. PFE | 11 | $292 |
| UCB, Inc. UCB.BR | 2 | $166 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $88.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.